UBS analyst Joshua Spector upgraded Chemours to Buy from Neutral with a price target of $43, up from $31.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CC:
- BofA shakes up ratings to get ‘more offensive’ in U.S. Chemicals
- Chemours upgraded to Buy from Neutral at BofA
- Chemours downgraded to Sector Perform from Outperform at RBC Capital
- Chemours price target raised to $33 from $30 at Citi
- Chemours ‘tracking slightly below’ low end of FY22 adjusted EBITDA, FCF guidance